Innovations in synthesis technology and gene synthesis have become a powerful and valuable means of obtaining genetic material.
List view / Grid view
Issue #3 2019
Filter the results
It is predicted that there will be 70 new monoclonal antibody (mAb) biotherapeutics available by 2020.
A significant hurdle in optimising antibody therapeutics is the screening of successive rounds of large libraries of mutant variants in order to recognise the ideal candidate.
The number of oligonucleotide-based platforms on the market is constantly increasing and has led to the emergence of innovative nucleic acid-based therapeutic modalities such as CRISPR-Cas, sgRNAs or mRNAs.
This issue includes an investigation into utilising recombinant antibodies for research, a highlight on protein design using computational methods and an examination of the advances in genomic medicine. Also in the issue are articles on next generation sequencing and upstream bioprocessing.